DEF 14A: Exicure Inc. Seeks Stockholder Approval for $8.7 Million HiTron Investment Amid Delisting Concerns

Exicure, Inc. is seeking stockholder approval for a $8.7 million investment from HiTron Systems Inc., which would result in a change of control and is crucial for the company to avoid delisting from Nasdaq and potential bankruptcy.

Summary

• Exicure, Inc. is holding a special meeting on December 17, 2024, to seek stockholder approval for a proposed $8.7 million investment from HiTron Systems Inc.
• The investment involves the issuance of 2,900,000 new shares of common stock at $3.00 per share to HiTron.
• If approved, HiTron will become the majority shareholder, owning approximately 61% of Exicure's common stock.
• The company needs this capital to fund operations, pursue strategic alternatives, and maintain its Nasdaq listing.
• Failure to approve the deal could lead to delisting, bankruptcy, or cessation of operations.
• HiTron previously invested $1.3 million in Exicure, acquiring 433,333 shares at $3.00 per share and gaining the right to appoint two board members and a chief restructuring officer.
• The company has until December 17, 2024, to demonstrate compliance with Nasdaq listing requirements.
• The board recommends voting in favor of the proposal.

Sentiment

Score: 3

Explanation: The document conveys a sense of urgency and desperation, highlighting the company's dire financial situation and reliance on the HiTron investment to avoid delisting and potential bankruptcy. While the investment is a positive step, the overall tone is negative due to the significant risks and uncertainties involved.

Positives

• The $8.7 million investment from HiTron would provide crucial funding for Exicure's operations and strategic alternatives.
• The investment could help Exicure regain compliance with Nasdaq listing requirements and avoid delisting.
• The deal would allow Exicure to continue as a going concern.
• HiTron's investment could lead to new strategic opportunities, including potential collaborations with Korean biotechnology firms.

Negatives

• The deal would result in a change of control, with HiTron becoming the majority shareholder.
• If the deal is not approved, Exicure faces a high likelihood of delisting from Nasdaq and potential bankruptcy.
• The company has not identified any other potential financing sources willing to make a similar investment.
• Exicure has sold substantially all of its historical biotechnology assets in September 2024, relying on uncertain future royalties and license payments.

Risks

• Failure to secure stockholder approval for the HiTron investment could lead to delisting from Nasdaq.
• The company may need to seek bankruptcy protection or cease operations if the deal is not approved.
• There is no guarantee that the company will be successful in its appeal to the Nasdaq Hearings Panel.
• The company's future revenue is uncertain, relying on potential royalties and license payments.
• HiTron may pursue investments or strategic transactions in industries unrelated to Exicure's historical operations.

Future Outlook

The company intends to use the proceeds for general corporate purposes and business development. HiTron plans to explore opportunities for collaboration with Korean biotechnology firms and may consider investments or strategic transactions in various industries and technologies, including those outside the U.S.

Management Comments

• The Board believes that completing the Purchase Agreement provides the best available opportunity for the Company and stockholders.
• The Company needs to raise substantial additional capital in the very near term to fund our operations and our pursuit of strategic alternatives.
• Given our current lack of a significant, ongoing revenue source or committed financing other than the Purchase Agreement, the Board believes that completing the Purchase Agreement provides the best available opportunity for the Company and stockholders.

Industry Context

This announcement comes as Exicure faces significant financial challenges and potential delisting from Nasdaq. The company's move to secure a major investment from HiTron reflects a trend of companies seeking strategic partnerships and capital infusions to navigate financial difficulties and pursue growth opportunities. The involvement of a South Korean company also highlights the increasing globalization of the biotechnology and investment sectors.

Comparison to Industry Standards

• The proposed investment of $8.7 million for 2,900,000 shares at $3.00 per share is a significant transaction for a company of Exicure's size, especially given its current financial situation.
• The change of control resulting from HiTron's majority ownership is a common outcome in distressed situations where a company needs a substantial capital injection.
• The need to demonstrate compliance with Nasdaq listing requirements by December 17, 2024, is a critical deadline, similar to other companies facing delisting threats.
• The company's reliance on potential future royalties and license payments is a common risk for biotechnology companies that have sold off their assets.
• The lock-up period of 90 days for HiTron is a standard provision in such agreements to prevent immediate selling pressure on the stock.

Management Changes

Related Party Transactions

• HiTron recently purchased 433,333 shares of Common Stock from Exicure at a price of $3.00 per share for total proceeds of $1.3 million.
• Exicure entered into a common stock purchase agreement with HiTron on November 13, 2024, for the issuance of 2,900,000 shares at $3.00 per share for total proceeds of $8.7 million.

Stakeholder Impact

• Shareholders face the risk of significant dilution if the HiTron investment is approved.
• Shareholders also face the risk of delisting and potential loss of investment if the deal is not approved.
• Employees may be impacted by potential restructuring or changes in the company's direction.
• Creditors may be impacted by the company's financial instability and potential bankruptcy.
• Customers and suppliers may be impacted by the company's uncertain future.

Next Steps

• Stockholders will vote on the Purchase Agreement Proposal and the Adjournment Proposal at the Special Meeting on December 17, 2024.
• The company will need to demonstrate compliance with Nasdaq listing requirements by December 17, 2024.
• If the Purchase Agreement is approved, the company will proceed with the issuance of shares to HiTron and explore strategic alternatives.
• The company will file a registration statement with the SEC for the resale of shares purchased by HiTron within 60 days of the closing.

Key Dates

Keywords

Exicure, HiTron, stockholder approval, investment, change of control, Nasdaq delisting, capital raise, common stock, strategic alternatives, bankruptcy